Brief cognitive behavior therapy for stigmatization, depression, quality of life, social support and adherence to treatment among patients with HIV/AIDS: a randomized control trial

Abstract

Objective Individuals living with HIV/AIDs are at a high risk of many problems like depression, stigma, quality of life, decreased adherence to treatment, and lack of social support. The present study aimed to investigate the impact of brief-cognitive behavior therapy (B-CBT) on reducing depression and stigma and improving treatment adherence, quality of life, and social support among patients with HIV/AIDS attending antiretroviral therapy (ART). Materials and methods This randomized clinical trial was conducted at ART Clinic in the Tehsil Headquarters Hospital Shahkot Nankana Sahib from July 2021 to October 2021. After baseline screening, 126 patients met the eligibility criteria and 63 were allocated to the experimental group (EXPg = 63) and 63 to waitlist-control group (WLCg = 63). Participants’ age range was from 20 to 55 years. Participants who were taking ART treatment were enrolled for the CBT treatment. Before this, all the participants completed a baseline assessment to ensure a level of severity and diagnosis. A total of eight CBT based therapeutic sessions were conducted individually with EXPg. To assess the outcomes among patients receiving ART, we used Demographic form, Patient health questionnaire, HIV stigma scale, General medication adherence scale, Multidimensional scale of perceived social support, and WHOQOL BREF scale. Results Findings suggest that B-CBT significantly reduced the level of depression (i.e. F (1, 78) = 101.38, p < .000, η2 = .599), and social stigma (i.e. F (1, 78) = 208.47, p < .000, η2 = .787) among patients with HIV/AIDS. Furthermore, CBT substantially improved the level of adherence to treatment (i.e. F(1,78) = 24.75, p < .000, η2 = .503), social support (i.e. F (1, 78) = 128.33, p < .000, η2 = .606), and quality of life (i.e. F (1, 78) = 373.39, p < .000, η2 = .837) among patients with HIV/AIDS. Significant mean difference M(SD) on PHQ at post-analysis in the EXPg vs. WLCg was seen 1.22(0.47) vs. 2.30(0.68) and similarly, on MPSS at a post-analysis in the EXPg vs. WLCg 2.85(0.36) vs. 1.70(0.51) which indicates sound therapeutic outcomes. Conclusions Cognitive behavioral therapy effectively decreases the level of depression and stigma and enhances the level of social support, quality of life, and adherence to treatment among HIV/AIDS patients. It is concluded that cognitive behavior therapy is an effective treatment approach for patients with HIV/AIDS. Trial registration Thai clinical trial registry (i.e. TCTR = TCTR20210702002).

“I want to be healthy and move on”: A qualitative study of barriers and facilitators to antiretroviral treatment adherence among young adult survivors with perinatal HIV in Thailand

“…Cultural appropriate intervention to reduce stigma in the community that involves people living with HIV in designing and implementation is also required [ 32 ]. Stigma-reduction interventions for YPHIV might include cognitive behavioral therapy to boost self-esteem and improve stress management, which was reported from studies in low-middle-income countries as an effective approach [ 33 , 34 ].…”

Process evaluation of the HIV+D intervention for integrating the management of depression in routine HIV care in Uganda

“…The intervention model consisted of psychoeducation, Behavioural Activation, antidepressant medication and referral to mental health workers; delivered in a stepped care fashion. The therapies have previously been shown to be effective against depression in primary care settings including in HIV care [26][27][28][29].…”

Pharmacokinetics and Safety of Ainuovirine/Lamivudine/Tenofovir Combination Tablets in Young and Elderly Patients with Human Immunodeficiency Virus-1 Infection

“…Human immunodeficiency virus-1 (HIV-1) infection is a global health challenge that affects millions of people worldwide. Since the first case of AIDS was reported, more than 79.3 million people worldwide have been infected with HIV-1 and 36.3 million have died from HIV-related illnesses [ 1 , 2 ]. By 2022, a total of 39.0 million people were living with HIV-1 [ 3 , 4 ].…”